Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

Clinical trial NCT05323955 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05323955
Sponsor: Carey Anders, M.D.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Brain Metastases Human Epidermal Growth Factor 2 Positive Carcinoma of Breast Advanced Breast Cancer

Start date: 2023-03-23
Primary completion: 2026-11-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.